# IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

> **NCT04258111** · PHASE2 · TERMINATED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** IBI310 (anti-CTLA-4 antibody)
- **BIOLOGICAL:** Sintilimab(anti-PD-1 antibody)

## Key facts

- **NCT ID:** NCT04258111
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-27
- **Primary completion:** 2020-10-26
- **Final completion:** 2020-10-26
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** After careful consideration, our company has decided to revise the overall development strategy for IBI310 and discontinue further registration research for this project. Consequently, the ongoing screening process will be terminated, and this decisi
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04258111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04258111, "IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04258111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*